Core Viewpoint - Yong'an Pharmaceutical is focusing on the dual development model of "contract manufacturing services" and "self-owned brand operations" through its subsidiary Yong'an Health, aiming to enhance market recognition and sustainable development capabilities in the health industry [1] Group 1: Business Development - Yong'an Health has been actively expanding its online and offline channels for its brand "Yijiani," which is positioned in the anti-fatigue functional solid beverage segment [1] - The company plans to increase investment in its self-owned brand business while continuing to develop its contract manufacturing services [1] Group 2: Financial Performance - In the first half of 2025, Yong'an Pharmaceutical reported revenue of approximately 367 million yuan, a year-on-year decrease of 13.72% [1] - The net profit attributable to the parent company was approximately 12.5 million yuan, reflecting a significant year-on-year decline of 76.19% [1] Group 3: Management Update - On September 3, Yong'an Pharmaceutical announced that the chairman, Chen Yong, has had the detention measures lifted by the Hekou County Supervisory Committee, allowing him to resume his duties [2] - The company's production and operational status remains normal following this development [2]

Market Overview - The Shanghai Composite Index rose by 0.52% on September 30, with 19 out of 28 sectors experiencing gains, led by the non-ferrous metals and defense industries, which increased by 3.22% and 2.59% respectively [1] - The pharmaceutical and biological industry saw an increase of 1.40% [1] - The sectors with the largest declines were telecommunications and non-bank financials, which fell by 1.83% and 1.14% respectively [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 32.303 billion yuan, with only four sectors seeing net inflows [1] - The defense industry had the highest net inflow of 2.059 billion yuan, while the non-ferrous metals sector followed with a net inflow of 1.984 billion yuan [1] - The non-bank financial sector experienced the largest net outflow, totaling 11.405 billion yuan, followed by telecommunications with a net outflow of 5.936 billion yuan [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector had a net inflow of 984 million yuan, with 310 out of 475 stocks rising, including two hitting the daily limit [2] - The top three stocks by net inflow were WuXi AppTec with 1.113 billion yuan, followed by Hengrui Medicine and Yong'an Pharmaceutical with 431 million yuan and 134 million yuan respectively [2] - Nine stocks in this sector saw net outflows exceeding 50 million yuan, with C Jianfa Zhi leading at 896.727 million yuan [3] Top Gainers in Pharmaceutical Sector - WuXi AppTec increased by 6.42% with a turnover rate of 2.86% and a main capital flow of 1.112 billion yuan [2] - Hengrui Medicine rose by 3.40% with a turnover rate of 0.91% and a main capital flow of 431 million yuan [2] - Yong'an Pharmaceutical saw a rise of 6.92% with a turnover rate of 16.56% and a main capital flow of 134 million yuan [2] Top Losers in Pharmaceutical Sector - C Jianfa Zhi decreased by 15.04% with a turnover rate of 52.49% and a main capital flow of -896.727 million yuan [3] - Xiangrikui rose by 2.00% but had a net outflow of 854.806 million yuan [3] - Jilin Aodong fell by 1.91% with a net outflow of 797.945 million yuan [3]

Group 1 - The chemical pharmaceutical sector increased by 1.63% on September 30, with Mengke Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3882.78, up 0.52%, while the Shenzhen Component Index closed at 13526.51, up 0.35% [1] - Notable gainers in the chemical pharmaceutical sector included Mengke Pharmaceutical, which rose by 8.45% to a closing price of 9.11, and Yong'an Pharmaceutical, which increased by 6.92% to 18.08 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 256 million yuan from main funds, while retail investors experienced a net outflow of 320 million yuan [2] - Key stocks with significant main fund inflows included Heng Rui Pharmaceutical with 37.4 million yuan and Yong'an Pharmaceutical with 134 million yuan [3] - Conversely, stocks like ST Suwu and ST Fuhua experienced declines of 5.00% and 4.97%, respectively, indicating a mixed performance within the sector [2]

Group 1 - The core viewpoint of the article highlights the performance of the Zhongzheng 2000 ETF Enhanced (159556), which rose by 0.69% to 1.169 yuan with a trading volume of 597,400 yuan as of the midday close on September 30 [1] - The top holdings of the Zhongzheng 2000 ETF Enhanced include Zhihua New Materials, which increased by 6.49%, and Hengbao Co., which decreased by 1.47% [1] - The fund's performance benchmark is the Zhongzheng 2000 Index return, managed by Ping An Fund Management Co., with a return of 16.56% since its establishment on December 27, 2023, and a return of -1.02% over the past month [1]

Key Points - Huasoft Technology is currently producing and selling light initiator products in small batches based on customer orders [1] - Kaineng Health plans to establish a wholly-owned subsidiary in Hainan or Hunan provinces to engage in the cell industry and related mergers and acquisitions [1] - Linyang Energy has won a bid for a 142 million yuan project with the State Grid [1] - New Zhizhi Software intends to acquire 49% equity of Shenzhen Hengdao for 48.2356 million yuan [1] - Xindian Software plans to repurchase shares worth between 30 million to 50 million yuan [1] - Shanjin International has submitted an application for the issuance and listing of H-shares on the Hong Kong Stock Exchange [1] - Zhongwei Semiconductor has also submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [1] - Huadong Heavy Machinery's Wu Qingming Yu No. 6 and Tianchen Jinting No. 1 plan to reduce their holdings by no more than 1.5% [2] - Xinde New Materials' Shang Rong Baoying and its concerted parties plan to reduce their holdings by no more than 3% [2] - Huayi Pharmaceutical's shareholder Wang Xiaopeng plans to reduce his holdings by no more than 12.708 million shares [2] - International Industry plans to raise no more than 660 million yuan through a private placement to its controlling shareholder [2] - Ruima Precision has been awarded a project for automotive air suspension system products [2] - Wanhui High-tech expects a net profit increase of 69.81% to 109.77% for the first three quarters [2]

Policy Developments - The National Healthcare Security Administration (NHSA) has announced a public solicitation for information on innovative medical consumables, including brain-machine interface technologies and surgical robots, to streamline the coding process for these products [2] Drug and Device Approvals - Fosun Pharma's subsidiary, Fosun Kary, has had its drug registration application for Brexucabtagene Autoleucel accepted by the National Medical Products Administration, aimed at treating relapsed or refractory B-cell acute lymphoblastic leukemia in adults [4] - Novogene's subsidiary has received medical device registration certificates for several neurodiagnostic reagents, which can assist in diagnosing Alzheimer's and Parkinson's diseases [5] Capital Market Activities - Hengrui Medicine has signed a licensing agreement for its innovative drug SHR-A1811, receiving an upfront payment of $18 million and potential milestone payments up to $1.093 billion, which will enhance its overseas market presence [7] - Yong'an Pharmaceutical plans to acquire a 49.20% stake in its subsidiary Ling'an Technology for 27 million yuan, aiming to strengthen control and reduce management costs [8] Industry Events - The NHSA hosted discussions with domestic and international investment institutions, emphasizing support for the high-quality development of innovative drugs and the implementation of policies to facilitate this growth [10] - Illumina has announced partnerships with several global pharmaceutical companies to develop companion diagnostics based on its TruSight Oncology genomic testing platform, focusing on KRAS gene mutations [11] Regulatory and Governance Updates - The former deputy director of the Henan Provincial Medical Security Bureau is under investigation for serious violations of discipline and law [13] - Shareholder Wang Xiaopeng of Huyou Pharmaceutical plans to reduce his stake by up to 3% due to personal financial needs [14] - Independent director Huang Zhengming of Qidi Pharmaceutical has resigned due to work reasons, which may affect the board's composition [15]

Mergers and Acquisitions - Huatian Technology is planning to acquire Huy Microelectronics, a subsidiary of its controlling shareholder, through a share issuance and cash payment, which is expected to constitute a related party transaction but not a major asset restructuring. The company's stock will be suspended from trading starting September 25 [1] - Dalong Real Estate's subsidiary intends to acquire 60% equity of Beijing Chengzhu Real Estate Development Co., Ltd. from Beijing Shunyi New Town Development Co., Ltd. to enhance project reserves and operational capabilities [2] - Yong'an Pharmaceutical plans to acquire 49.2% equity of its subsidiary Hubei Ling'an Technology Co., Ltd. from minority shareholders for 27 million yuan, aiming for full ownership [3] - Rongxin Culture's wholly-owned subsidiary intends to acquire 51% equity of Wuhan Youxue Baobei Book Co., Ltd. for 16.32 million yuan, which will be consolidated into the company's financial statements post-transaction [4] Shareholding Changes - Huyou Pharmaceutical's shareholder Wang Xiaopeng plans to reduce his stake by up to 3%, equivalent to a maximum of 12.708 million shares [5] - Beimo High-tech's shareholder Chen Jianfeng intends to reduce his stake by up to 2.49%, which amounts to a maximum of 8.2666 million shares [6] - Donghua Energy's controlling shareholder, Mansen Energy (Zhangjiagang), has increased its stake by 0.34%, acquiring 5.3093 million shares for approximately 45.6488 million yuan [7] Risk Matters - Zhangjiang Hi-Tech has announced a potential irrational speculation risk as its stock price has deviated significantly from industry peers and the Shanghai Composite Index, with a cumulative price increase of 20% over three consecutive trading days [8] - *ST Gaohong faces a risk of delisting as its stock price has been below 1 yuan for 18 consecutive trading days, with a potential delisting if the market capitalization remains below 500 million yuan for 20 consecutive trading days [9] - *ST Yatai's controlling shareholder's voting rights have decreased due to a forced sale of shares by a court, although this will not lead to a change in control or governance structure at this time [10]

（编辑 任世碧） 证券日报网讯 9月24日晚间，永安药业发布公告称，公司于2025年9月24日召开第七届董事会第九次临 时会议，审议通过了《关于收购控股子公司少数股东股权暨对外投资的议案》。基于战略规划与业务发 展需要，公司拟使用自有资金2，700万元收购控股子公司湖北凌安科技有限公司（简称"凌安科技"）少 数股东张勇、夏昌培、代亮合计持有的凌安科技49.20%股权，并签署《股权转让协议》。本次股权转 让完成后，公司将持有凌安科技100%股权，公司合并报表范围未发生变化。本次交易事项无需提交公 司股东会审议。 ...

Core Points - Yong'an Pharmaceutical Co., Ltd. announced adjustments to its business scope and board composition to enhance governance efficiency and adapt to operational needs [1][2] - The company plans to expand its business scope to include drug wholesale, import and export, and production and sales of pharmaceutical excipients, among other activities [1] - The board of directors will increase from 6 to 7 members, adding one employee representative director and one vice chairman, while the supervisory board will be abolished [1][2] Business Scope Adjustments - The previous business scope included the production and sales of APIs, food additives, and feed additives, as well as self-produced and sold products like ethylene oxide [1] - The new scope will include licensed projects such as drug wholesale and pharmaceutical excipients, along with general projects like chemical product production and technical services [1] Governance Enhancements - The company will revise parts of its articles of association, including increasing the number of board members and abolishing the supervisory board [1][2] - Eleven governance documents will be revised or established, including rules for shareholder meetings and board meetings, with three requiring shareholder approval [2]

格隆汇9月24日丨永安药业(002365.SZ)公布，公司拟使用自有资金2,700万元收购控股子公司湖北凌安科 技有限公司（简称"凌安科技"或"标的公司"）少数股东张勇、夏昌培、代亮合计持有的凌安科技49.20% 股权，并签署《股权转让协议》。本次股权转让完成后，公司将持有凌安科技100%股权，公司合并报 表范围未发生变化。 ...